Kendall Capital Partners

Rounds

• C CentivaxDevelops a universal flu vaccine and broad immunity platform $37MVenture · 25 Mar
• C CentivaxBiotech developing a universal flu vaccine using a proprietary immune-targeting platform. $45MSeries A · 8 Jul

No round matches these filters.

Often invests with

• Amplify Partners1
• Base4 Capital1
• BOLD Capital Partners1
• Future Ventures1
• John Collison1
• Meiji Seika Pharma1
• NFX1
• Patrick Collison1